Evidence map›Paper›PMID 35354090›Full record

ReviewTranslational research : the journal of laboratory and clinical medicine2022

Microfluidic methods to advance mechanistic understanding and translational research in sickle cell disease.

Melissa Azul, Eudorah F Vital, Wilbur A Lam, David K Wood, Joan D Beckman

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Translational research : the journal of laboratory and clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Melissa AzulDepartment of Pediatrics, Mayo Clinic, Rochester, Minnesota.
Eudorah F VitalWallace H. Coulter Department of Biomedical Engineering and Institute for Electronics and Nanotechnology, Georgia Institute of Technology and Emory University, Atlanta, Georgia.
Wilbur A LamWallace H. Coulter Department of Biomedical Engineering and Institute for Electronics and Nanotechnology, Georgia Institute of Technology and Emory University, Atlanta, Georgia.
David K WoodDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota.
Joan D BeckmanDepartment of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota. Electronic address: beckm092@umn.edu.
University of Minnesota · USGeorgia Institute of Technology · USMayo Clinic · USThe Wallace H. Coulter Department of Biomedical Engineering · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM008169 · NIGMS · EMORY UNIVERSITY · PI GROSS, ROBERT E · 1987 to 2021
$20.3M
Medical Scientist Training ProgramT32GM142617 · NIGMS · EMORY UNIVERSITY · PI Jason Yustein · 2022 to 2026
$7.0M
Engineering biophysical microtechnologies for hematologic applications in health and diseaseR35HL145000 · NHLBI · EMORY UNIVERSITY · PI LAM, WILBUR A · 2019 to 2025
$5.0M
Developing a multiscale understanding of biophysical processes in sickle cell diseaseR01HL132906 · NHLBI · UNIVERSITY OF MINNESOTA · PI WOOD, DAVID KEVIN · 2017 to 2024
$4.6M
Redefining Clinical Viscosity in Sickle Cell Diseaseby Leveraging Microfluidic TechnologiesR01HL140589 · NHLBI · EMORY UNIVERSITY · PI LAM, WILBUR A, WOOD, DAVID KEVIN · 2018 to 2021
$3.0M
Circulating Endothelial Cells and Microvesicles as Biomarkers for Gene Therapy in Sickle Cell DiseaseOT2HL152758 · NHLBI · UNIVERSITY OF MINNESOTA · PI BELCHER, JOHN D · 2019 to 2020
$408k
A microfluidic platform to study sickle blood rheologyR56HL132906 · NHLBI · UNIVERSITY OF MINNESOTA · PI WOOD, DAVID KEVIN · 2016 to 2016
$402k
A New Paradigm to Treat Bleeding by Augmenting Hemostasis via Microscale Electrical FieldsF31HL158223 · NHLBI · EMORY UNIVERSITY · PI VITAL, EUDORAH · 2021 to 2024
$209k
NHLBI NIH HHS F31 HL158223NHLBI NIH HHS OT2 HL152758NHLBI NIH HHS R01 HL132906NHLBI NIH HHS R01 HL140589NHLBI NIH HHS R35 HL145000NHLBI NIH HHS R56 HL132906NIGMS NIH HHS T32 GM008169NIGMS NIH HHS T32 GM142617
6 · The paper itself

Abstract

Sickle cell disease (SCD) is caused by a single point mutation in the β-globin gene of hemoglobin, which produces an altered sickle hemoglobin (HbS). The ability of HbS to polymerize under deoxygenated conditions gives rise to chronic hemolysis, oxidative stress, inflammation, and vaso-occlusion. Herein, we review recent findings using microfluidic technologies that have elucidated mechanisms of oxygen-dependent and -independent induction of HbS polymerization and how these mechanisms elicit the biophysical and inflammatory consequences in SCD pathophysiology. We also discuss how validation and use of microfluidics in SCD provides the opportunity to advance development of numerous therapeutic strategies, including curative gene therapies.

Indexed as

Anemia, Sickle CellMicrofluidicsHemoglobin, SickleHemolysisHumansTranslational Research, BiomedicalHemoglobin, Sickle

Identifiers

PMID35354090
PMCPMC9218997
OpenAlexW4220790401

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.